In a live taping of the Science Will Win podcast, Host and Artificial Intelligence Expert Jeremiah Owyang speaks to cutting-edge healthcare leaders about the impact that AI is having on the future of cancer. Thirty years ago, the thought of a world without cancer was nothing more than a dream. Similarly, AI was considered a technology that had yet to become reality. Today, we are reimagining a future where the AI revolution will help change the trajectory of cancer as we know it.

Featured experts:

• Edward Cox, Head & General Manager Of Digital Health & Medicines, Pfizer
• Julie Gerberding, CEO and President, Foundation for the National Institutes of Health
• Maimah Karmo, Founder & CEO, Tigerlily Foundation

This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge. 

Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare.

Featured Guests:

• Dame Sally Davies, UK Special Envoy for Antimicrobial Resistance
• Daniel Gallego, President of the European Kidney Patient Federation
• Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer
• Subha Madhavan, Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data Management
• Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development.

Featured Guests:

• Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
• Lei Zhang, Executive Director of Medicinal Chemistry, Pfizer Medicine Design
• Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance. 

Featured Guests:

• Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
• Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer
• Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence.

Featured Guests:

• Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
• Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs
• Mary Lynne Van Poelgeest-Pomfret, President, World Federation of Incontinence and Pelvic Problems

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.

Featured Guests:

• Martha Carlson, Breast Cancer Advocate & Writer
• Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
• Jeff Settleman, Chief Scientific Officer, Pfizer Oncology

In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?

Featured Guests:

• Laurie, Breast Cancer Clinical Trial Participant
• Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
• Julia Perkins Smith, Global Clinical Lead, Pfizer
• Jamil Rivers, CEO, Chrysalis Initiative

Additional Resources:

• pfizerclinicaltrials.com/oncology
• pfizerclinicaltrials.com
• pfizerestudiosclinicos.com

Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!

In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Bob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer 
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer